Pioneering the Future of Gastrointestinal Health
Understanding Barrett’s Esophagus
#1 Risk for Developing Esophageal Cancer
As acids and enzymes leak or reflux back into the esophagus, patients may develop GERD (Gastro Esophageal Reflux Disease). It is common for patients with GERD to develop Barrett’s Esophagus. Barrett’s Esophagus is a primary risk factor for esophageal cancer.
Scientists from the International Agency for Research on Cancer (IARC), project esophageal cancer cases to increase by over 50% by 2040, reaching nearly 1 million new cases annually worldwide.
Understanding Esophageal Cancer
C-WAVE Therapy
Convective Water Vapor Energy (C-WAVE) Therapy uses the energy that is created in a few drops of heated water to ablate tissue in the GI Tract. C-WAVE is designed for the ablation of Barrett’s Esophagus.
A new standard of care for the treatment of Barrett’s Esophagus to improve the lives of patients around the world.
CORSA Inc. is a Minneapolis-based Company that has developed patented Convective Water Vapor Energy (C-WAVE) to dramatically improve the ease, efficiency, and efficacy of treating Barrett’s Esophagus, reducing the risk of esophageal cancer for millions of patients around the world.
Scott Herring, CEO
“Extensive data demonstrates that Ablation Therapy is a safe and effective approach to reduce the risk of progression of Barrett’s Esophagus to Esophageal Cancer. It’s an exciting time in the field as advances in diagnostic tools, precision medicine, and AI will drive improved risk stratification and broader adoption of Ablation Therapy for higher-risk patients. We’re excited to introduce C-WAVE Therapy to improve the ease, efficiency, and efficacy of Ablation Therapy.”
— Scott Herring, CEO